Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Systematic review and meta-analysis of tocilizumab in persons with coronavirus disease-2019 (COVID-19)
Chongxiang Chen, Fang‐Wen Hu, Jin Wei, et al.
Leukemia (2021) Vol. 35, Iss. 6, pp. 1661-1670
Open Access | Times Cited: 22

Showing 22 citing articles:

COVID-19 Therapeutics: Use, Mechanism of Action, and Toxicity (Vaccines, Monoclonal Antibodies, and Immunotherapeutics)
Michael Chary, Alexander F. Barbuto, Sudeh Izadmehr, et al.
Journal of Medical Toxicology (2023) Vol. 19, Iss. 2, pp. 205-218
Open Access | Times Cited: 19
The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial
Johanna Hammersen, Sebastian Birndt, Konstanze Döhner, et al.
Leukemia (2023) Vol. 37, Iss. 9, pp. 1879-1886
Open Access | Times Cited: 11
Effect of Tocilizumab in Reducing the Mortality Rate in COVID-19 Patients: A Systematic Review with Meta-Analysis
Valeria Conti, Graziamaria Corbi, Carmine Sellitto, et al.
Journal of Personalized Medicine (2021) Vol. 11, Iss. 7, pp. 628-628
Open Access | Times Cited: 17
The Pathogenetic Dilemma of Post-COVID-19 Mucormycosis in India
Sankha Shubhra Chakrabarti, Upinder Kaur, Sushil Kumar Aggarwal, et al.
Aging and Disease (2022) Vol. 13, Iss. 1, pp. 24-24
Open Access | Times Cited: 11
Efficacy of tocilizumab in the treatment of COVID‐19: An umbrella review
Mohammad Mahdi Rezaei Tolzali, Maryam Noori, Pourya Shokri, et al.
Reviews in Medical Virology (2022) Vol. 32, Iss. 6
Open Access | Times Cited: 11
Impact of the Addition of Baricitinib to Standard of Care Including Tocilizumab and Corticosteroids on Mortality and Safety in Severe COVID-19
Mar Masiá, Sergio Padilla, José Alberto García, et al.
Frontiers in Medicine (2021) Vol. 8
Open Access | Times Cited: 15
Initiation of Tocilizumab or Baricitinib Were Associated With Comparable Clinical Outcomes Among Patients Hospitalized With COVID-19 and Treated With Dexamethasone
Carlos King Ho Wong, Kristy T. K. Lau, Ivan Chi Ho Au, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 10
High-Dose Dexamethasone Versus Tocilizumab in Moderate to Severe COVID-19 Pneumonia: A Randomized Controlled Trial
Naveen Naik B, Goverdhan D Puri, Kamal Kajal, et al.
Cureus (2021)
Open Access | Times Cited: 13
Efficacy and safety of tocilizumab in hospitalized COVID-19 patients: A systematic review and meta-analysis
Lili Luo, Ting Luo, Mengyi Du, et al.
Journal of Infection (2021) Vol. 84, Iss. 3, pp. 418-467
Open Access | Times Cited: 12
Should We Interfere with the Interleukin-6 Receptor During COVID-19: What Do We Know So Far?
Alexia Plocque, Christie Mitri, Charlène Lefèvre, et al.
Drugs (2022) Vol. 83, Iss. 1, pp. 1-36
Open Access | Times Cited: 8
IMPACT of PCSK9 inhibition on clinical outcome in patients during the inflammatory stage of the SARS-COV-2 infection: Rationale and protocol of the IMPACT-SIRIO 5 study
Jacek Kubica, Przemysław Podhajski, Przemysław Magielski, et al.
Cardiology Journal (2021) Vol. 29, Iss. 1, pp. 140-147
Open Access | Times Cited: 11
Outcomes associated with tocilizumab with or without corticosteroid versus dexamethasone for treatment of patients with severe to critical COVID-19 pneumonia
Hajar AlQahtani, Sara Albilal, Ebrahim Mahmoud, et al.
Journal of Infection and Public Health (2021) Vol. 15, Iss. 1, pp. 36-41
Open Access | Times Cited: 10
Inflammation in COVID-19: A Risk for Superinfections
Mariana Boulos, Tamara Bassal, Asad Layyous, et al.
COVID (2022) Vol. 2, Iss. 11, pp. 1609-1624
Open Access | Times Cited: 6
Course of inflammation and infection markers differ in ICU patients with severe COVID-19 under casirivimab- and/or tocilizumab application: an observational study
Stana-Nicoleta Iustila-Maran, Amelie Orlet, Karl Traeger, et al.
Research Square (Research Square) (2024)
Open Access
COMPARATIVE SAFETY EFFICACY OF CONVENTIONAL AND TRADITIONAL MEDICINE FOR COVID-19 TREATMENT: UMBRELLA REVIEW
Bukhari Bukhari, Sartika Maulida Putri, Asnawi Abdullah, et al.
International Journal of Medical Science and Public Health Research (2024) Vol. 05, Iss. 06, pp. 8-26
Open Access
Interleukin-6 Inhibitor Olokizumab in Hospitalized Adults with Moderate COVID-19: Results of a Single Center Observational Study
S. V. Topolyanskaya, Svetlana Rachina, K. A. Lytkina, et al.
West Kazakhstan Medical Journal (2024) Vol. 66, Iss. 4, pp. 453-459
Open Access
Tocilizumab effectiveness in mechanically ventilated COVID-19 patients (T-MVC-19 Study): a multicenter real-world evidence
Yahya Mohzari, Ahmad Alamer, Majda Alattas, et al.
Expert Review of Anti-infective Therapy (2022) Vol. 20, Iss. 7, pp. 1037-1047
Open Access | Times Cited: 2
An Integrated View of Virus-Triggered Cellular Plasticity Using Boolean Networks
Jenny Paola Alfaro-García, María Camila Granados-Alzate, Miguel Vicente‐Manzanares, et al.
Cells (2021) Vol. 10, Iss. 11, pp. 2863-2863
Open Access | Times Cited: 2
Efficacy and Safety of Tocilizumab in Severe Covid-19 Infection in Second and Third Wave of Epidemics in Myanmar: Multicenter Randomized Controlled Trial
Khin Phyu Pyar, Aung Phyoe Kyaw, Nyan Lin Maung, et al.
Biomedical Research and Clinical Reviews (2022) Vol. 6, Iss. 3, pp. 01-18
Open Access
Tocilizumab, riesgo de intubación y sobrevida en pacientes con Neumonía por COVID-19
Maynor Palma, Edgar Contreras, Johanna Samayoa, et al.
Revista médica (Colegio de Médicos y Cirujanos de Guatemala) (2022) Vol. 161, Iss. 2, pp. 118-123
Open Access
Interleukin-6 inhibitors: from the therapy of immuno-inflammatory rheumatic diseases to use in COVID-19
N. V. Muravyevа, Б. С. Белов
Meditsinskiy sovet = Medical Council (2022), Iss. 11, pp. 88-94
Open Access
Tocilizumab as a breakthrough in the cytokine storm of COVID-19 pneumonia- Case series in the intensive care unit
Michell Gulabani, Richa Chauhan, Ashok Kumar Saxena
Indian Journal of Clinical Anaesthesia (2022) Vol. 9, Iss. 3, pp. 382-386
Open Access
Page 1

Scroll to top